prime DX

The prime DX new technology for tumor molecular profiling is compatible with both FFPE and PLASMA.

Prime DX is designed to give to the physician an overall outlook on treatment response for:
• Targeted therapy
• Immunotherapy
• Chemotherapy


prime DX

The new prime DX assay is a 1021- Gene Variant panel that also analyzes immunotherapy biomarkers PD-L1, TMB, MSI, HLA. In Addition, it includes Loss of Heterozygosity (LOH) analysis, which can be used as biomarker for PARP inhibitor treatment and is designed to give to the physician an overall outlook on treatment response for:

  • Targeted therapy
  • Immunotherapy
  • Chemotherapy

It is one of the most detailed, sensitive and specific tests for tumor biology configuration, enabling physicians to plan an efficient treatment for the patient, including immunotherapy, chemotherapy, PARP inhibitors and clinical trial participation compatibility.

Finally, it gives answers about the toxicity of chemotherapy drugs, such as 5-FU, irinotecan and others.




















Who should be tested



This test is designed for the following cases:

  • Aggressive tumors with no standard treatment
  • Patients with advanced solid tumor
  • Second-line or post-line treatment
  • Rare Tumors
  • Tumors of unknown primary tumor
  • Tumors with many available treatment options, where the physician must clarify the most effective one based on the individual tumor profile of each patient.

Why prime DX

Choose the right cancer treatment: prime DX multi-gene assay provides a comprehensive picture of the tumor biology. This helps physicians and patients choose a personalized cancer treatment.

It analyzes 1021 unique cancer genes and the HLA, MSI, PD-L1, TMB and LOH biomarkers.

This way the physician has a clear indication of which treatments will benefit the patient and which not, including immunotherapy.

Continuous support to the doctor and the patient from our experienced team.
The procedure for prime DX test or any other test at Genekor Medical S.A. does not end with the results report.

Our experienced customer service and scientific consulting teams work with the physician and patient throughout the process. Both teams guide the patient throughout the examination process and provide information on new data and recommended treatments on a case-by-case basis, creating a strong support system for both.

State of the art, sensitive and reliable technology: The new prime DX assay is based on advanced molecular technology using hybridization with UMIs.
It analyzes biomarkers for immunotherapy response , including detection of HLA and biomarkers for chemotherapy response.
MGI-DNBSEQ-G400 new technology allows the lab to run a heavy load of multiple samples simultaneously and with higher sensitivity (Hotspot: VAF ≥2%) allowing to receive faster, reliable results at a lower cost.
This is a state of the art technology, which has demonstrated high reproducibility, sensitivity and specificity and has been adopted by the leading cancer institutions worldwide.


In order to view the Table of Genes included in prime DX Assay please click here.

For more scientific and technical information you can contact us:

For more information about PrIMe Test please visit:

PrIMe Test
Change cookies consent Revoke cookies consent